Roche buys us firm for $ 8.3 billion

The pharmaceutical company closed purchase agreement with the American biotechnology company InterMune for $ 8.3 billion. The offer is the biggest deal made by Swiss laboratory since 2009, when he acquired 44% of American Genentech for $ 47 billion. The two companies already work together in developing a drug against hepatitis C since 2006. Each Labs are also close, both in the u.s. and in Switzerland, which will facilitate the integration, according to the President of the group, Severin Schwan. Drugmakers are buying their rivals to gain sales volume and breadth of expertise.